Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
The efficacy of a recombinant vaccinia virus (rvv-GM-CSF) expressing the granulocyte macrophage colony stimulating factor (GM-CSF) as tumor vaccine was evaluated in the murine B16-F10 melanoma model. The vaccine was prepared by infection of irradiated tumor cells with rvv-GM-CSF. Control vaccine was B-16 cells infected with a recombinant vaccinia virus expressing Escherichia coli beta-galactosidase (rvv-lacZ). Pre-vaccination of naive C57BL/6 mice later inoculated with tumor cells and treatment of mice bearing tumors with GM-CSF vaccine inhibited tumor development and prolonged survival. Lung metastasis of B-16 was also inhibited by treatment with GM-CSF vaccine. The vaccine effects appeared to be tumor cell specific. The efficacy of the vaccine was comparable to a retroviral vaccine (MFG-muGM-CSF) in this system. The vaccine was also effective when rvv-GM-CSF was directly injected into the tumor. These data suggest that this vaccine approach has potential for use in cancer treatment, especially for patients with easily accessible tumors.
Chatterjee
S K
SK
Department of Internal Medicine, Lucille Parker Markey Cancer Center, University of Kentucky Medical Center, Lexington 40536, USA.
Qin
H
H
Manna
S
S
Tripathi
P K
PK
D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics* / Q000627:therapeutic use; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics*; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy; D008546:Melanoma, Experimental / Q000473:pathology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D011995:Recombination, Genetic; D014616:Vaccinia virus / Q000235:genetics*
D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor